EMA Validates Taletrectinib Application for ROS1+ NSCLC, UK and Canada Filings Planned
Nuvation Bio and Eisai received EMA validation of the Marketing Authorisation Application for taletrectinib in advanced ROS1-positive NSCLC, triggering a standard review timeline. Additional filings are planned in the U.K., Canada and Eisai’s territories, broadening market access beyond the existing U.S., China and Japan approvals.
1. EMA Validates MAA for Taletrectinib
Nuvation Bio and Eisai secured validation of their Marketing Authorisation Application from the European Medicines Agency, initiating the standard review process for taletrectinib’s use in advanced ROS1-positive non-small cell lung cancer across Europe.
2. Expanded Regulatory Filings Planned
Following the EMA submission, the partners will file for approval in the U.K., Canada and additional territories within Eisai’s license, including regions across the Middle East, North Africa, Russia, Southeast Asia and Australia, targeting broader global market access.
3. Clinical Evidence and Existing Approvals
The application is backed by pooled Phase 2 data from the TRUST-I and TRUST-II trials demonstrating significant objective response rates, and taletrectinib is already fully approved for advanced ROS1+ NSCLC in the U.S., China and Japan.